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The rise in opioid-related overdose deaths 
in the last two decades is widely regarded 
as an epidemic that originated with the 
overprescribing of prescription pain relievers 
in the late 1990s. But a research study 
published in the September issue of Science 
suggests that the opioid overdose crisis is 
actually part of a larger trend that started 
40 years ago.1
 In the study, researchers mapped 
drug overdose deaths in the U.S. from 1979 
through 2016. The authors analyzed data 
from the National Vital Statistics System on 
599,255 deaths in which the main cause of 
death was listed as accidental drug poisoning. 
The authors found that drug overdose 
fatalities have been increasing dramatically 
since 1979, stating that “this exponentially 
increasing mortality rate has tracked along a 
remarkably smooth trajectory for at least 38 
years,” suggesting that “the current wave of 
opioid overdose deaths may just be the latest 
manifestation of a more fundamental longer-
term process.”2 
 Within this broad trend of steady 
growth, there is significant variation in 
terms of the specific drugs involved and 
the populations most affected by drug 
overdose deaths. Currently, the population 
most at risk for cocaine overdose is aging 
black males living in urban counties, while 
methamphetamine-related deaths skew 
toward white and rural male populations. 
For opioid-related deaths, age is a defining 
feature of variation in risk patterns. Deaths 
involving heroin and synthetic opioids are 
higher for people between the ages of 20 
and 40, especially white males living in 
urban counties. In contrast, prescription 
opioid deaths are higher among those 40 to 
60 years old, especially white females living 
in rural counties. Nearly every region of the 
country, except for the northern Midwest, 
has been a “hot spot” for drug overdose 
deaths in the last few years. 
 Despite some limitations,3 this analysis 
provides strong evidence for the existence 
of a protracted drug epidemic that 
requires both immediate and long-term 
interventions. The finding that the relatively 
recent increase in opioid-specific overdoses 
may be a particularly intense manifestation 
of a more persistent problem implies that a 
major feature of the government response 
to opioid-involved overdoses—restricting 
the supply of prescription painkillers—does 
little to stem the overall uptick in drug-
related fatalities. The fact that the increase 
in overdose deaths has remained constant 
despite varying trends for specific drugs 
also suggests that factors often thought to 
drive the overdose epidemic, such as a rise 
in drug use or an overabundant drug supply, 
are not sufficient explanations.
 
OVERDOSE DEATHS VS. DRUG USE 
Overdose deaths are a “relatively reliable” 
measure of the most serious consequences 
of drug epidemics because U.S. states count 
all overdose deaths.4 However, analysis of 
overdose death data does not capture other 
features of drug epidemics, such as patterns 
of drug use. One of the most reliable and 
longest serving sources of data on drug use 
patterns is the National Survey on Drug Use 
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 Further analysis of the relationship 
between drug use patterns and overdose 
deaths is needed. It is possible that the 
NSDUH data underestimate rates of drug use 
and SUDs in the population. Trends identified 
in large data sets also tell us little about the 
specific circumstances of individuals who 
become addicted or have a fatal overdose. 
But the divergence in growth of drug 
overdose deaths compared to drug use and 
SUD rates suggests that this epidemic is 
less about overall drug use and more about 
specific patterns of drug use behavior that 
increase the risk of overdose.
REDUCING OVERDOSES: IMMEDIATE 
INTERVENTIONS
Current trends indicate that one of the 
biggest challenges to stemming overdose 
deaths is the ubiquity of powerful synthetic 
opioids, such as fentanyl and carfentanil, in 
the black market drug supply. To address 
this problem, elected officials are calling 
for enhanced efforts to reduce the amount 
of fentanyl and fentanyl analogs coming to 
the U.S. from overseas.9 Any reduction in 
the supply of these very deadly drugs could 
save lives, so it is reasonable to devote some 
resources to curtailing their availability. But 
the diversity of distribution outlets makes 
this an uphill battle, and drug manufacturers 
and traffickers will likely adapt to any 
successful efforts to restrict fentanyl by 
finding a drug alternative that is potentially 
just as lethal, if not more so. To be sure of 
the high likelihood of this scenario, we need 
look no further than the current spike10 in 
fentanyl-related overdose deaths, which 
is a consequence of government efforts to 
reduce the supply of prescription opioids in 
the early 2000s. 
 Given the dangers of today’s illicit 
drugs, and the fact that their eradication 
is impossible, it is critical to focus on 
reducing the risk of overdose associated 
with their use. One risk factor for overdose 
that is becoming increasingly common is 
polydrug use.11 The mixing of drugs that 
have synergistic effects, such as opioids and 
benzodiazepines, is especially toxic. In this 
case, both drugs are sedatives that restrict 
and Health (NSDUH), which surveys roughly 
70,000 people annually about their drug use 
and mental health. These data suggest that 
rates of drug use have not kept pace with 
the rates of overdose deaths. 
 The total number of people aged 12 or 
older reporting past-month illicit drug use 
(including marijuana) increased from 25.4 
million in 1979 to 28.6 million in 2016.5 As 
a percentage of the population, this is a 
decrease from 14.1 percent to 10.6 percent. 
For most drug categories, fewer people report 
past-month use in 2016 than in 1979. For 
example, even though more people now say 
they have tried cocaine at least once, fewer 
people use it with any regularity—there were 
an estimated 4.7 million past-month users in 
1979 compared to 1.9 million in 2016. 
 This downward trend in past-month 
illicit use holds for all drug categories except 
heroin and prescription pain relievers. Only 
0.2 percent of the population aged 12 or 
older misused heroin in the past month in 
2016, but the total number of past-month 
users increased from 128,000 in 1979 
to 475,000 in 2016. In addition, the total 
number of people who misused prescription 
pain relievers in the past month increased 
from 2.7 million in 1985 (1.2 percent of 
the population) to 3.4 million in 2016 (1.4 
percent of the population), an increase 
roughly consistent with population growth.6 
The number of past-month users of heroin 
and prescription pain relievers also has 
not increased steadily but has waxed and 
waned over the decades, albeit with a more 
constant increase since around 2002. 
 People with a substance use disorder 
(SUD) are at a higher risk of overdose than 
occasional or regular users, but SUD rates in 
the population have also been stable. The 
number of people with an SUD involving an 
illicit drug (including marijuana) has been 
relatively constant between 7.1 million in 
2002 and 7.4 million in 2016.7 The number 
of people with an SUD involving either 
prescription opioids or heroin increased 
from 1.7 million in 2002 to 2.1 million in 
2016, an increase of roughly 24 percent. By 
comparison, the rate of overdose deaths 
involving an opioid increased 254 percent 
during that same time period, from 11,920 in 
2002 to 42,249 in 2016.8 
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breathing, which is one cause of overdosing. 
Over 30 percent of deaths involving 
opioids also involve a benzodiazepine, and 
over 95 percent of deaths involving a 
benzodiazepine involve at least one other 
drug, with opioids being the class of drugs 
most frequently mentioned.12 The mixing 
of different opioids, of opioids and cocaine, 
and of opioids or cocaine with alcohol, 
can also be deadly; data indicate that for 
all three major classes of drugs (opioids, 
benzodiazepines, and stimulants), the 
majority of overdose deaths involves two or 
more drugs.13
 Trends of polysubstance use evident 
in overdose fatality data highlight the need 
for policy responses that specifically target 
this pattern of drug use. Some people may 
be unaware of their exposure to multiple 
drugs; for example, they may not know 
that the Xanax (a commonly prescribed 
benzodiazepine) or the Vicodin (a commonly 
prescribed opioid) they purchased off the 
street or the internet are actually counterfeit 
pills containing fentanyl. One relatively 
new way of addressing this problem is to 
distribute fentanyl test strips, which allow 
people to test drugs prior to their use. A 
study of a program in Vancouver that 
hands out test strips found that users who 
got a positive result for fentanyl were 10 
times more likely to lower their dose of 
drugs.14 In addition to providing such testing 
mechanisms, public health campaigns 
should discourage polysubstance use and 
encourage safe use practices, but many 
public officials still bristle at the idea of 
promoting drug-related information that is 
not abstinence-based.
 Other methods of reducing opioid-
related overdoses are well established. 
Providing users with access to the overdose 
reversal drug naloxone,15 safe consumption 
areas,16 and medication-assisted treatment17 
are considered best practices by many drug 
addiction and public health experts. While 
there is more support for such interventions 
now compared to 20 years ago, they have 
been implemented unevenly across the U.S., 
and the federal government has yet to invest 
fully in such efforts. 
 At the same time, the finding that 
the increase in overdose deaths predates 
the rise in opioid-related deaths should 
serve as a warning to not focus reduction 
efforts exclusively on opioids. Yet most 
government-funded initiatives to address 
the overdose epidemic have targeted opioids 
specifically18 and have neglected other drugs 
that are increasingly implicated in overdoses, 
such as cocaine19 and methamphetamine. 
The ability to address cocaine and meth-
related overdoses is limited by the fact 
that medical interventions do not exist for 
these drugs like they do for opioids. But 
the data make it apparent that policies to 
curb overdose deaths should focus less on 
a specific drug and more on the problem of 
heavy and risky drug use behavior.
REDUCING OVERDOSES: LONG-TERM 
SOLUTIONS 
The decades-long upward trend in overdose 
deaths offers compelling evidence that 
complex forces are operating together to 
drive these deaths. That the increase has 
been so persistent, despite large variations 
in the trajectories of individual drugs, 
suggests that any successful efforts to 
reduce the drug supply are quickly offset 
by market adaptations and changes in 
consumer preferences. 
 Even though drug use and addiction 
rates have not grown as fast or as steadily 
as overdose rates, it is generally true that 
those who use more drugs more frequently 
are at greater risk of an overdose. Thus, part 
of the long-term approach to this problem 
must focus on factors driving demand, 
particularly for heavy and risky drug use 
that increases the chances of overdose.
 Unfortunately, current public policies 
are remarkably ineffective at reducing both 
casual and compulsive drug use. There are 
few existing government interventions that 
can significantly reduce the extent to which 
people experiment with drugs, although 
public health campaigns that provide factual 
information on drug risks, especially to 
youths, are generally appropriate. Instead 
of treating all drug use behaviors, from 
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reporting across states and counties, but 
when the analysis is limited to the states 
that report better quality data from 1999 to 
2016, the exponential trend still holds. It is 
also possible that overdose deaths involving 
more than one drug are counted more 
than once in the analysis. Data collection 
on specific drugs involved in accidental 
overdose deaths did not begin until 1999, so 
it is not possible to identify trends involving 
specific drugs prior to that year.
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 6. “The Brian C. Bennett Drug Charts,” 
The Baker Institute for Public Policy, 
last modified May 2018, https://www.
bakerinstitute.org/bennett-charts/.
 7. Center for Behavioral Health Statistics 
and Quality, 2016 National Survey. 
 8. “Drug Overdose Deaths in the United 
States, 1999-2016,” Centers for Disease 
Control and Prevention, https://www.cdc.
gov/nchs/data/databriefs/db294_table.pdf. 
 9. J.D. Prose, “Toomey bill penalizes 
fentanyl exporters, specifically calling 
out China,” The Times Online, September 
23, 2018, http://www.timesonline.com/
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out-china.
 10. “Synthetic Opioid Overdose Data,” 
Centers for Disease Control and Prevention, 
December 16, 2016, https://www.cdc.gov/
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 11. Hawre et al., “Changing dynamics of 
the drug overdose epidemic,” 1218. 
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National Institute on Drug Abuse, March 
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opioids; Margaret Warner, James P. Trinidad, 
Brigham A. Bastian, Arialdi M. Miniño, and 
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Involved in Drug Overdose Deaths: United 
experimentation to addiction, as if they carry 
the same risks, and rather than treating 
drug addiction as if it affects everyone 
equally, policy interventions should focus on 
preventing the progression from occasional 
to problematic drug use among populations 
most vulnerable to addiction. 
 Despite demographic variability 
in overdose deaths, the populations 
consistently at greatest risk for addiction 
are those living with economic insecurity,20 
a history of trauma,21 or mental illness.22 
Policies intended to reduce problematic 
patterns of drug use, then, must address 
systemic issues underlying these problems, 
such as the loss of jobs that provide a livable 
income, the lack of adequate health care 
coverage for all ailments and for mental 
health in particular, and the increasing 
sense of isolation that people feel from 
community and civic life.23 Government 
policies cannot solve all of the problems 
that may drive a person’s desire to escape 
an unpleasant reality through drug use, but 
they can improve upon current conditions. 
Doing so will require a heavy investment, 
but one that is necessary if we are to 
protect against future drug-related deaths. 
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